RESUMEN
Histidine decarboxylase (HDC) is the single enzyme responsible for histamine synthesis. HDC-deficient mice (HDC(-/-)) have no histamine in their tissues when kept on a histamine-free diet. Therefore, the HDC(-/-) mice provide a suitable model to investigate the involvement of histamine in the regulation of histamine receptor expression. Gene expression of H1 and H2 histamine receptors was studied in several organs of HDC(-/-) mice and compared to standard (HDC(+/+)) mice. In many tissues, prolonged absence of histamine induced down-regulation of the H2 receptor subtype. The expression of the H1 receptor was less sensitive to histamine deficiency. Exogenous histamine present in the diet abolished the differences observed in H2 receptor expression. These results suggest that the expression of mouse H2 receptor is under the control of histamine in a tissue-specific manner.
Asunto(s)
Cimetidina/análogos & derivados , Regulación hacia Abajo , Histamina/metabolismo , Histidina Descarboxilasa/deficiencia , Receptores Histamínicos H2/genética , Receptores Histamínicos H2/metabolismo , Animales , Cimetidina/metabolismo , Eliminación de Gen , Perfilación de la Expresión Génica , Histidina Descarboxilasa/genética , Histidina Descarboxilasa/metabolismo , Ratones , Ratones Noqueados , Especificidad de Órganos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The involvement of histamine in cancer growth represents an old controversy and direct experimental evidence proving this hypothesis is not still available. In this paper we review the most relevant mechanisms referring to the role of histamine receptors, histidine decarboxylase and histamine release in the onset of an autocrine loop, that enables histamine to act as an autocrine growth factor. We postulate that this autocrine loop, that has been studied in an experimental mammary carcinoma model induced in rats, may be present in different human neoplasias. Therefore, the better understanding of this novel regulatory pathway that is controlled by histamine may contribute to identifying new therapeutic targets.
Asunto(s)
Comunicación Autocrina/fisiología , Sustancias de Crecimiento/fisiología , Histamina/fisiología , Animales , Liberación de Histamina , Histidina Descarboxilasa/metabolismo , Ratones , Neoplasias/metabolismo , Ratas , Receptores Histamínicos/metabolismoAsunto(s)
Calcio/farmacología , Diferenciación Celular/efectos de los fármacos , Queratinocitos/citología , Queratinocitos/metabolismo , Receptores Histamínicos H2/metabolismo , Animales , Células Epidérmicas , Proteínas de Unión al GTP/metabolismo , Ratones , Transducción de Señal , Células Tumorales CultivadasRESUMEN
The aim of this study was to develop an experimental model for the study of cancer associated with diabetes. For diabetes induction, Sprague-Dawley rats were given streptozotocin (STZ, 90 mg/kg body weight (BW), by intraperitoneal injection on the second day of life. For mammary tumour induction, rats were injected with 50 mg/kg BW of N-nitroso-N-methylurea (NMU) at 50, 80 and 110 days old. The neoplastic process and the effect of tamoxifen treatment was examined in non-diabetic and diabetic rats. The latency period, NMU-induced tumour incidence and the number of tumours per rat in diabetic rats versus controls were 117 +/- 7 days versus 79 +/- 9 days (P < 0.001); 93% versus 95% (NS); and 5.2 +/- 1.6 versus 2.7 +/- 0.5 (P < 0.02). A more benign histological pattern for tumours in diabetic animals was observed. Mammary tumours in diabetic rats grew more slowly than in controls. Tamoxifen (1 mg/kg/day) treated diabetic rats showed tumour regression in 67% of NMU-induced mammary tumours versus 53% in controls (NS). Our results show that tumour progression seems to be affected by diabetes in this experimental model. We suggest this is the result of changes to insulin-like growth factors and their receptors, which occur in diabetics, and our future research will examine this hypothesis.
Asunto(s)
Anticarcinógenos/uso terapéutico , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Neoplasias Mamarias Experimentales/etiología , Tamoxifeno/uso terapéutico , Animales , Antibacterianos , Carcinógenos/toxicidad , División Celular , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Tipo 2/patología , Femenino , Insulina/sangre , Neoplasias Mamarias Experimentales/sangre , Neoplasias Mamarias Experimentales/patología , Metilnitrosourea/toxicidad , Ratas , EstreptozocinaAsunto(s)
Regulación Neoplásica de la Expresión Génica/genética , Genes ras/genética , Queratinocitos/metabolismo , Receptores Histamínicos/genética , Transducción de Señal/genética , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Animales , Carcinógenos/toxicidad , Cimetidina/análogos & derivados , Cimetidina/metabolismo , AMP Cíclico/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Genes ras/efectos de los fármacos , Agonistas de los Receptores Histamínicos/metabolismo , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos H1/metabolismo , Antagonistas de los Receptores H2 de la Histamina/metabolismo , Fosfatos de Inositol/metabolismo , Queratinocitos/efectos de los fármacos , Ratones , Mutación/efectos de los fármacos , Mutación/genética , Proteína Oncogénica p21(ras)/biosíntesis , Proteína Oncogénica p21(ras)/genética , Pirilamina/metabolismo , Receptores Histamínicos/efectos de los fármacos , Sistemas de Mensajero Secundario , Transducción de Señal/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
OBJECTIVE: In the present work we studied the association of histamine receptors with second messengers during multistage carcinogenesis in Sencar mice skin. METHODS: 96 Sencar female mouse, divided into six groups were used. Tumors appeared only in the 7, 12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted group. Control groups received only TPA, or acetone or no treatment at all. Periodically during the promotion period, cAMP and inositol phosphate production were measured after stimulation with H1 or H2 agonists in samples from all groups. RESULTS: In non-treated skin, H1 receptors were coupled to phosphatidylinositol hydrolysis and H2 receptors mediated cAMP production. Conversely, in tumors H2 receptors were associated with phosphatidylinositol hydrolysis and H1 mediated a rise in cAMP levels. The skin among tumors and the skin from all control groups maintained the same coupling as non-treated skin. An increase in mast cell number, with a homogeneous subepithelial distribution and marked phenotypic changes, was also observed in promoted skin. CONCLUSIONS: These findings indicate an atypical association of histamine receptors with second messengers that could be a critical feature for the postulated action of histamine in tumor growth.
Asunto(s)
Receptores Histamínicos H1/fisiología , Receptores Histamínicos H2/fisiología , Transducción de Señal/fisiología , Neoplasias Cutáneas/fisiopatología , 9,10-Dimetil-1,2-benzantraceno , Animales , Recuento de Células , Cimetidina/análogos & derivados , Cimetidina/metabolismo , AMP Cíclico/metabolismo , Femenino , Antagonistas de los Receptores Histamínicos H1/metabolismo , Antagonistas de los Receptores H2 de la Histamina/metabolismo , Hidrólisis , Mastocitos/patología , Ratones , Fosfatidilinositoles/metabolismo , Pirilamina/metabolismo , Sistemas de Mensajero Secundario , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/patología , Acetato de TetradecanoilforbolAsunto(s)
Carcinógenos/toxicidad , Histamina/fisiología , Histidina Descarboxilasa/biosíntesis , Neoplasias Mamarias Experimentales/enzimología , Metilnitrosourea/toxicidad , Análisis de Varianza , Animales , Northern Blotting , ADN Complementario/genética , ADN Complementario/metabolismo , Femenino , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/genética , Antagonistas de los Receptores Histamínicos H1/farmacología , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Antagonistas de los Receptores H2 de la Histamina/farmacología , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Histidina Descarboxilasa/antagonistas & inhibidores , Histidina Descarboxilasa/genética , Riñón/enzimología , Neoplasias Mamarias Experimentales/inducido químicamente , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Metilhistidinas/farmacología , Metilhistidinas/uso terapéutico , ARN Mensajero/análisis , Ratas , Útero/enzimologíaAsunto(s)
Neoplasias de la Mama/química , Mama/química , Histamina/fisiología , Receptores Histamínicos H1/análisis , Receptores Histamínicos H2/análisis , Mama/citología , Neoplasias de la Mama/patología , Línea Celular , Transformación Celular Neoplásica , Células Epiteliales , Epitelio/química , Humanos , Células Tumorales CultivadasRESUMEN
In order to determine the role of endogenous histamine in the regulation of cell growth, the in vitro action of fluoromethyl-histidine (MFMH) was studied in experimental mammary carcinomas induced in rats. Tumor cells were cultured in soft agar using the clonogenic agar technique. The MFMH was added in different concentrations (0.01-100 microM). The effect observed was a 60% inhibition on colony formation with a maximal effect at concentrations over 10 microM. This action was completely reverted by the H2 agonists dimaprit and arpromidine with an IC50 value of 1 microM. The action of the H2 agonists when added alone was a significant increase in cell proliferation (135%), while the H1 agonist produced a dose-dependent inhibition on cell growth. In these experimental carcinomas endogenous histamine is critical for cell proliferation and one of its major effects may be the stimulation of cell growth by acting on specific H2 membrane receptors.
Asunto(s)
Carcinoma/patología , Sustancias de Crecimiento/fisiología , Histamina/fisiología , Neoplasias Mamarias Experimentales/patología , Animales , Carcinoma/metabolismo , Femenino , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Neoplasias Mamarias Experimentales/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores Histamínicos/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
The presence of H1 and H2 histamine receptors and their associated second messenger systems were studied during the development of the rat mammary gland. In the tissue of the young female, histamine presented a double receptor site as previously described for experimental mammary tumors, namely a high affinity H2 site (Kd = 10 +/- 2 nM, Bmax = 1068 +/- 71 fm/mg prot.), which mediated its effect via the products of phosphoinositide hydrolysis and a low affinity H1 receptor (Kd1 = 5 +/- 2 nM, Bmax = 188 +/- 33 fm/mg prot. and Kd2 = 41 +/- 20 nM, Bmax = 1980 +/- 790 fm/mg prot. when characterized with 3H-mepyramine), coupled to adenylyl cyclase activation. On the other hand, the mammary gland of the adult rat presented these receptors coupled to the classical second messenger systems described for mammalian cells, that is, the H2 receptor produced an increase in intracellular cAMP levels and the H1 receptor increased the phosphoinositide turnover. We conclude that histamine plays a critical role during development and differentiation of the normal rat mammary gland.